PT058 Clinical Presentation, Predictors, And Outcomes of Aldosterone Therapy-Eligible Acute Heart Failure Patients: A Sub-Study of The Heart Function Assessment Registry Trial In Saudi Arabia (Hearts)

Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e177
Author(s):  
Khalid F. AlHabib ◽  
Hussam Alfaleh ◽  
Ahmad Hersi ◽  
Tarek Kashour ◽  
Abdulfattah Elasfar ◽  
...  
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Acute Heart Failure ◽  
Clinical Presentation ◽  
Heart Function ◽  
Heart Failure Patients ◽  
Function Assessment

scholarly journals Design and preliminary results of the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS) in patients with acute and chronic heart failure†

2011 ◽  
Vol 13 (11) ◽  
pp. 1178-1184 ◽  
Author(s):  
Khalid F. AlHabib ◽  
Abdelfatah A. Elasfar ◽  
Hanan AlBackr ◽  
Hussam AlFaleh ◽  
Ahmad Hersi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Chronic Heart Failure ◽  
Heart Function ◽  
Preliminary Results ◽  
Function Assessment

Clinical Presentation, Predictors, and Outcomes Among Mineralocorticoid Receptor Antagonist (MRA)-Eligible Acute Heart Failure Patients in the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS)

Angiology ◽  
2017 ◽  
Vol 69 (4) ◽  
pp. 323-332
Author(s):  
Mostafa Q. AlShamiri ◽  
Khalid F. AlHabib ◽  
Waleed AlHabeeb ◽  
Ismail R. Raslan ◽  
Anhar Ullah ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Saudi Arabia ◽  
Receptor Antagonist ◽  
Acute Heart Failure ◽  
Mineralocorticoid Receptor ◽  
Heart Function ◽  
Left Ventricular ◽  
Mineralocorticoid Receptor Antagonist ◽  
Term Survival

Mineralocorticoid receptor antagonist (MRA) therapy is indicated after myocardial infarction in patients with acute heart failure (AHF) with an ejection fraction ≤40% and lacking contraindications. We analyzed clinical presentations, predictors, and outcomes of MRA-eligible patients within a prospective registry of patients with AHF from 18 hospitals in Saudi Arabia, from 2009 to 2010. For this subgroup, mortality rates were followed until 2013, and the clinical characteristics, management, predictors, and outcomes were compared between MRA-treated and non-MRA-treated patients. Of 2609 patients with AHF, 387 (14.8%) were MRA eligible, of which 146 (37.7%) were prescribed MRAs. Compared with non-MRA-treated patients, those prescribed MRAs more commonly exhibited non-ST-segment elevation myocardial infarction, acute on chronic heart failure, past history of ischemic heart disease, and severe left ventricular systolic dysfunction; were more commonly administered oral furosemide and digoxin; and had higher in-hospital recurrent congestive HF rates. Mortality did not significantly differ ( P > .05) between groups. In Saudi Arabia, 37.7% of eligible patients received MRA treatment, which is higher than that in developed countries. The lack of long-term survival benefit raises concerns about systematic problems, for example, proper follow-up and management after hospital discharge, warranting further investigation.

Causes and associated risk factors of heart failure patients in Aljouf region of Saudi Arabia

2021 ◽  
pp. 185-189
Author(s):  
Md Sheikh ◽  
Manahel Alotaibi ◽  
Nouf Almutairi ◽  
Eid Aljohani ◽  
Omar Alruwaili ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Saudi Arabia ◽  
Heart Failure Patients ◽  
Associated Risk Factors

The pattern of acute heart failure as an emergency situation in Eastern Saudi Arabia

2019 ◽  
pp. 15-21
Author(s):  
Mohammed Alhashim ◽  
Hussain Almazyadi ◽  
Waleed Alshammari ◽  
Mohammed Alaissawi ◽  
Amina Abdulla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Saudi Arabia ◽  
Acute Heart Failure ◽  
Emergency Situation
Sign in / Sign up

Export Citation Format

Share Document